Boothbay Fund Management, LLC Rigel Pharmaceuticals Inc Transaction History

Boothbay Fund Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.67 - $3.19 $109,386 - $520,808	-163,263 Reduced 62.76%	96,883 $109,000
Q1 2022 May 16, 2022	BUY	$2.22 - $3.45 $467,112 - $725,917	210,411 Added 423.06%	260,146 $778,000
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $39,617 - $59,929	-16,787 Reduced 25.24%	49,735 $132,000
Q3 2021 Nov 15, 2021	SELL	$3.5 - $4.5 $6,769 - $8,703	-1,934 Reduced 2.83%	66,522 $241,000
Q2 2021 Aug 16, 2021	BUY	$3.09 - $4.54 $99,303 - $145,901	32,137 Added 88.49%	68,456 $297,000
Q1 2021 May 17, 2021	SELL	$3.35 - $4.93 $163,245 - $240,238	-48,730 Reduced 57.3%	36,319 $124,000
Q4 2020 Feb 12, 2021	SELL	$2.35 - $3.74 $290,864 - $462,907	-123,772 Reduced 59.27%	85,049 $298,000
Q3 2020 Nov 16, 2020	SELL	$1.78 - $4.13 $42,771 - $99,239	-24,029 Reduced 10.32%	208,821 $501,000
Q2 2020 Aug 14, 2020	BUY	$1.41 - $2.05 $22,278 - $32,389	15,800 Added 7.28%	232,850 $426,000
Q1 2020 May 15, 2020	BUY	$1.27 - $3.0 $194,870 - $460,323	153,441 Added 241.23%	217,050 $339,000
Q4 2019 Feb 14, 2020	BUY	$1.6 - $2.43 $101,774 - $154,569	63,609 New	63,609 $136,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.